Evidence map›Paper›PMID 42069615›Full record

ArticleHarm reduction journal2026

Crack/cocaine use to manage xylazine exposure in fentanyl in Connecticut: findings from a convergent mixed methods study.

Katherine Hill, Emma T Biegacki, Gabrielle Bogut, Elizabeth Znamierowski, Cameron Breen, River Rose, Corona Zhang, Lauretta E Grau, Jenna L Butner, Robert Heimer and 1 more

Abstract read
In one paragraph

Article in Harm reduction journal, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

11 authors.

Katherine HillDepartment of Epidemiology of Microbial Diseases, Yale School of Public Health, New Haven, CT, USA. k.hill@yale.edu.
Emma T BiegackiYale Program in Addiction Medicine, Yale School of Medicine, New Haven, CT, USA.
Gabrielle BogutDepartment of Epidemiology of Microbial Diseases, Yale School of Public Health, New Haven, CT, USA.
Elizabeth ZnamierowskiDepartment of General Internal Medicine, Yale School of Medicine, New Haven, CT, USA.
Cameron BreenLiberation Programs, Bridgeport, CT, USA.
River RoseConnecticut Harm Reduction Alliance, Hartford, CT, USA.
Corona ZhangAlliance for Living, New London, CT, USA.
Lauretta E GrauDepartment of Epidemiology of Microbial Diseases, Yale School of Public Health, New Haven, CT, USA.
Jenna L ButnerDepartment of General Internal Medicine, Yale School of Medicine, New Haven, CT, USA.
Robert HeimerDepartment of Epidemiology of Microbial Diseases, Yale School of Public Health, New Haven, CT, USA.
Kimberly L SueYale Program in Addiction Medicine, Yale School of Medicine, New Haven, CT, USA.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

backgroundIn the context of the fourth wave of the opioid overdose crisis, defined by fentanyl and stimulant co-use, we aimed to explore if there might be a relationship between exposure to xylazine in the fentanyl supply and patterns of crack/cocaine use.

methodsThis mixed methods study used data from four Connecticut-based sources: (1) the Office of the Chief Medical Examiner for fatal overdoses, 2019-2023, (2) community-based drug checking data, 2023-2024, (3) a structured survey of people who use drugs, 2024, and (4) one-on-one in-depth interviews, 2024.

resultsXylazine was detected in 19.2% of overdose fatalities involving fentanyl or a fentanyl analog (n = 5,849). Those with xylazine detected had a higher proportion of cocaine simultaneously detected, though this was not statistically significant (54.0% vs. 51.1%, p = 0.085). Cocaine detection rose over time in the fatality data, regardless of xylazine detection. There were 1,048 drug samples submitted to harm reduction organizations for drug checking. Using Fourier Transform Infrared Spectroscopy, 573 of the samples submitted tested positive for fentanyl or a fentanyl analog; 45.2% of these also tested positive for xylazine. Of 1048 samples, 276 tested positive for cocaine. Among the survey sample (n = 88), 62.5% of participants self-reported xylazine exposure. Those who reported lifetime xylazine exposure also reported higher past-year crack/cocaine use, though this was not statistically significant (89.1% vs. 81.8%, p = 0.336). Among our interview sample (n = 31), three themes emerged: (1) participants felt there was an inevitability of polysubstance use due to an increasingly volatile drug supply, (2) participants increased their crack/cocaine use in response to perceived exposure to xylazine in their fentanyl supply, and (3) participants' drug patterning changed due to xylazine's presence (e.g., timing, drug sequencing, etc.). Two meta-inferences were identified: (1) overdose fatality data likely underestimate the "true" prevalence of xylazine in the street supply, and (2) people who use drugs are using crack/cocaine in response to xylazine in their local fentanyl supply.

conclusionsXylazine exposure has likely contributed to an adaptive and increasing use of crack/cocaine among people who use drugs in Connecticut. It is imperative that practitioners and policymakers are prepared to manage this triad of opioid-stimulant-sedative polysubstance use.

Indexed as

Cocaine-Related DisordersCrack CocaineDrug OverdoseFentanylOpioid-Related DisordersXylazineAdultAnalgesics, OpioidConnecticutFemaleHumansMaleMiddle AgedYoung AdultAnalgesics, OpioidCrack CocaineFentanylXylazineCocaineCrackFentanylHarm reductionStimulantsXylazine

Identifiers

PMID42069615
PMCPMC13289556

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.